Expression profiling correlates with treatment response in XXXX with advanced @entity43 .

@entity43 @entity1 @entity39697 @entity5 @entity29096
The majority of @entity43 are of serous subtype, with most @entity1 presenting at an advanced stage. Approximately 70% respond to initial chemotherapy but eventually relapse. We aimed to find markers of treatment response that might be suitable for routine use, using the gene expression profile of @entity5 tissue. Thirty one @entity1 with histologically-confirmed late-stage serous @entity43 were classified into 3 groups based on response to treatment (nonresponders, responders with relapse less than 12 months and responders with no relapse within 12 months). Gene expression profiles of these specimens were analyzed with respect to treatment response and survival (minimum 36 months follow-up). @entity1 ' clinical features did not correlate with prognosis, or with specific gene expression patterns of their @entity5 . However @entity1 who did not respond to treatment could be distinguished from those who responded with no relapse within 12 months based on 34 gene transcripts (p < 0.02). Poor prognosis was associated with high expression of @entity29096 ( @entity29096 ) (p = 0.001). High expression of @entity39697 (DCN) and @entity29096 together was strongly associated with reduced survival (p = 0.003), with an estimated 7-fold increased risk of dying (95% CI 1.9-29.6; 14 months survival) compared with low expression (44 months). Immunohistochemical analysis revealed both nuclear and cytoplasmic distribution of @entity29096 in @entity43 . High percentage of nuclear staining was associated with poor survival, although not statistically significantly. In conclusion, elevated expression of @entity29096 and DCN was significantly associated with poor prognosis in a homogeneous group of @entity43 @entity1 for whom survival could not be predicted from clinical factors.
